

in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

Repopulation of the Irradiation Damaged Lung with Bone Marrow-derived Cells. M.E. BERNARD, H. KIM, M.S. RAJAGOPALAN, B. STONE, U. SALIMI, J.-C. RWIGEMA, M.W. EPPERLY, H. SHEN, J.P. GOFF, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, H. WANG, D.B. STOLZ, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

15-Lipoxygenase-1 Induces Lipid Peroxidation and Apoptosis, and Improves Survival in Rat Malignant Glioma. H. VIITA, A. PACHOLSKA, F. AHMAD, J. TIETÄVÄINEN, J. NAARALA, A. HYVÄRINEN, T. WIRTH, S. YLÄ-HERTTUALA (*Kuopio; Joensuu, Finland*)

Identification of Four Isoforms of Aldolase B Down-regulated in Hepatocellular Carcinoma Tissues by Means of Two-dimensional Western Blotting. Y. WANG, Y. KURAMITSU, M. TAKASHIMA, Y. YOKOYAMA, N. IIZUKA, T. TAMESA, I. SAKAIDA, M. OKA, K. NAKAMURA (*Ube, Japan*)

Effects of Polo-like-kinase-1-inhibitor BI 2536 in Squamous Cell Carcinoma Cell lines of the Head and Neck- first In Vitro Results. J. WAGENBLAST, D. HIRTH, L. THRON, C. ARNOLDNER, M. DIENSTHUBER, T. STÖVER, M. HAMBEK (*Frankfurt am Main, Germany; Vienna, Austria*)

Expression Patterns and Potential Action of the Calcium Transport Genes Trpv5, Trpv6, Ncx1 and Pmca1b in the Canine Duodenum, Kidney and Uterus. J.-A. KIM, H. YANG, I. HWANG, E.-M. JUNG, K.-C. CHOI, E.-B. JEUNG (*Chungbuk, Republic of Korea*)

Association of IGF Axis Hormones with Waist-to-Hip Ratio Varies by Physical Activity. K.H. SCHMITZ, D. XIE, V. TEAL, R. BALLARD-BARBASH, D. BERRIGAN (*Philadelphia, PA; Bethesda, MD, USA*)

Post-operative Corticosterone Levels in Plasma and Feces of Mice Subjected to Permanent Catheterization and Automated Blood Sampling. R. SUNDBOM, K.R. JACOBSEN, O. KALLIOKOSKI, J. HAU, K.S.P. ABELSON (*Uppsala, Sweden; Copenhagen, Denmark*)

Familial Hodgkin's Lymphoma in Scandinavia. V. JÖNSSON, H. AWAN, E. NYQUIST, M. MAISENHÖLDER, T.B. JOHANNESSEN, B. LY, G.E. TJÖNNFJORD (*Oslo, Norway*)

Repair of Postauricular Defects Using a New Technique: The Swallowtail Flap. C. MONARCA, M. MARUCCIA, F. PALUMBO, N. SCUDERI (*Rome, Italy*)

Adipocyte-derived Factor as a Modulator of Oxidative Estrogen Metabolism: Implications for Obesity and Estrogen-dependent Breast Cancer. H.L. BRADLOW, D.W. SEPKOVIC, N. TELANG, R. TIWARI (*New York, NY, USA*)

No Cytomegalovirus Detected in the Gastrointestinal Tract of Patients with Active Crohns Disease. M.T. AARNIO, J.P. BÖHM, K.P. NUORVA, R.I. PITKÄNEN, T.H. KUOPIO, M.E. VOUTILAINEN (*Jyväskylä, Finland*)

Colon Cancer Vaccines: An Update (Review). E. MERIKA, M.W. SAIF, A. KATZ, C. SYRIGOS, M. MORSE (*London, UK; Haven, CT; Durham, NC, USA; Athens, Greece*)

Animal Models of N-Methyl-N-Nitrosourea-induced Mammary Cancer and Retinal Degeneration with Special Emphasis on Therapeutic Trials (Review). A. TSUBURA, OY.-C. LAI, H. MIKI, T. SASAKI, N. UEHARA, T. YURI, K. YOSHIZAWA (*Moriguchi, Osaka, Japan*)

Canine Mammary Tumours as a Model to Study Human Breast Cancer: Most Recent Findings (Review). F.L. QUEIROGA, T. RAPOSO, M.I. CARVALHO, J. PRADA, I. PIRES (*Vila Real, Portugal*)

Metastatic Potential of Orthotopic and Heterotopic Models Imaged by GFP and RFP Protein (Review). V. BOBEK, K. KOLOSTOVA, D. PINTEROVA, M. BOUBELIK, R. GURLICH, R.M. HOFFMAN (*Prague, Czech Republic; San Diego, CA, USA*)

Serotonin Transporter Polymorphism in Major Depressive Disorder (MDD), Psychiatric Disorders, and in MDD in Response to Stressful Life Events: Causes and Treatment with Antidepressant (Review). A. DANIELE, R. DIVELLA, A. PARADISO, V. MATTIOLI, F. ROMITO, F. GIOTTA, P. CASAMASSIMA, M. QUARANTA (*Bari, Italy*)

In Vivo Research Using Early Life Stage Models (Review). R. SEABRA, N. BHOGAL (*Nottingham, UK*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinassios
 International Institute of Anticancer Research (IIAR)
 Editorial Office of ANTICANCER RESEARCH,
 IN VIVO, CANCER GENOMICS and PROTEOMICS.
 1st km Kapandritiou-Kalamou Road
 P.O. Box 22, GR-19014 Kapandriti, Attiki
 GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

www.cgp-iiarjournals.com

Print ISSN: 1109-6535
Online ISSN: 1790-6245
VOL. 1 (2004) - VOL. 9 (2012)



General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our websites www.cgp-journals.com; www.iiar-anticancer.org and www.iiarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. e-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Free specimen copies of CGP are available on request.

A Selection of Recent Papers

KRAS Mutation is Associated with Elevated Myeloblastin Activity in Human Lung Adenocarcinoma. T. WIEDL, S. COLLAUD, S. HILLINGER, S. ARNI, C. BURGESS, W. KROLL, P. SCHRAML, A. SOLTERMANN, H. MOCH, W. WEDER (*Zurich, Switzerland; Cambridge, MA, USA*)

Early detection of Ovarian Cancer in Pre-diagnosis Samples Using CA125 and MALDI MS Peaks. J.F. TIMMS *et al* (*London; Reading, UK*)

Decoding Differentially Regulated Epithelial and Stromal Pathways in Colorectal Cancer. M. ABBA, S. LAUFS, M. AGHAJANY, B. KORN, A. BENNER, H. ALLGAYER (*Heidelberg, Germany*)

New Gene Groups Associated with Dissimilar Osteoblastic Differentiation Are Linked to Osteosarcomagenesis. F. LUK, Y. YU, H.- T. DONG, W.R. WALSH, J.- L. YANG (*Sydney, NSW, Australia*)

Small Molecule Inhibition of Cytoskeletal Dynamics in Melanoma Tumors Results in Altered Transcriptional Expression Patterns of Key Genes Involved in Tumor Initiation and Progression. C. SPENCER, J. MONTALVO, S.R. MCLAUGHLIN, B.A. BRYAN (*Worcester, MA, USA*)

Gene Expression Profile Can Predict Pathological Response to Preoperative Chemoradiotherapy in Rectal Cancer. M. NISHIOKA, M. SHIMADA, N. KURITA, T. IWATA, S. MORIMOTO, K. YOSHIKAWA, J. HIGASHIJIMA, T. MIYATANI (*Tokushima, Japan*)

Gene Expression Profiling and its Utility in Prediction of Local Relapse after Breast-conserving Therapy in Early Breast Cancer. R. SABATIER, P. FINETTI, N. CERVERA, A. TALLET, M. BENCHALAL, G. HOUVENAEGHEL, J. JACQUEMIER, D. BIRNBAUM, F. BERTUCCI (*Marseille; Rennes, France*)

Restoration of Senescence in Breast and Ovarian Cancer Cells Following the Transfer of the YAC Carrying SEN6A Gene Located at 6q16.3. N.S. RANE, A.K. SANDHU, V.S. ZHAWAR, G. KAUR, N.C. POPESCU, R.P. KANDPAL, M. JHANWAR-UNIYAL, R.S. ATHWAL (*Philadelphia, PA; Bethesda, MD; Pomona, CA; Valhalla, NY, USA*)

Therapy-, Gender- and Race- specific microRNA Markers, Target Genes and Networks Related to Glioblastoma Recurrence and Survival. K.R. DELFINO, N.V.L. SERÃO, B.R. SOUTHEY, S.L. RODRIGUEZ- ZAS (*Urbana, IL, USA*)

Differential Splicing Generates New Transmembrane Receptor and Extracellular Matrix-related Targets for Antibody-based Therapy of Cancer (Review). U.H. WEIDLE, D. MAISEL, S. KLOSTERMANN, E.H. WEISS, M. SCHMITT (*Penzberg; Planegg-Martinsried; Munich, Germany*)

The Cancer Biomarker Osteopontin: Combination with Other Markers (Review). G.F. WEBER (*Cincinnati, OH, USA*)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma (Review). T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

TGF- β 1 Interactome: Metastasis and Beyond (Review). M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO- MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAL, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (*Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA*)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer (Review). N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara; Meldola, Italy*)

The Continuing Search for Predisposing Colorectal Cancer Variants (Review). S. PICELLI, S. VON HOLST, P. WESSENDORF (*Stockholm, Sweden*)

Intraoperative Ultrasound: Improved Resection Rates in Breast-conserving Surgery. C. EICHLER, A. HÜBBEL, V. ZARGHOONI, A. THOMAS, O. GLUZ, M. STOFF-KHALILI, M. WARM (<i>Cologne; Bonn; Berlin; Moenchengladbach, Germany</i>)	1051
Coxsackie Adenovirus Receptor Expression in Carcinomas of the Head and Neck. T. WUNDER, U. SCHUMACHER, R.E. FRIEDRICH (<i>Hamburg, Germany</i>)	1057
Serum Antioxidant Capacity and Oxidative Injury to Pulmonary DNA in Never-smokers with Primary Lung Cancer. K. ITO, T. YANO, Y. MORODOMI, T. YOSHIDA, M. KOHNO, A. HARO, Y. SHIKADA, T. OKAMOTO, R. MARUYAMA, Y. MAEHARA (<i>Fukuoka, Japan</i>)	1063
Peritoneal Carcinomatosis from Solid Pseudopapillary Neoplasm (Frantz's Tumour) of the Pancreas Treated with HIPEC. C. HONORE, D. GOERE, P. DARTIGUES, P. BURTIN, F. DUMONT, D. ELIAS (<i>Villejuif, France</i>)	1069
Cystic Teratoma of the Pancreas. J. SCHEELE, T.F.E. BARTH, M. WITTAU, M. JUCHEMS, D. HENNEBRUNS, M. KORNMANN (<i>Ulm, Germany</i>)	1075
WT1 Peptide Therapy for a Patient with Chemotherapy-resistant Salivary Gland Cancer. T. SHIRAKATA, Y. OKA, S. NISHIDA, N. HOSEN, A. TSUBOI, Y. OJI, A. MURAO, H. TANAKA, S.-I. NAKATSUKA, H. INOHARA, H. SUGIYAMA (<i>Ehime; Osaka; Tochigi; Hyogo, Japan</i>)	1081
Repeat Transrectal Ultrasound Biopsies with Additional Targeted Cores According to Results of Functional Prostate MRI Detects High-risk Prostate Cancer in Patients with Previous Negative Biopsy and Increased PSA – A Pilot Study. C. ARSOV, M. QUENTIN, R. RABENALT, G. ANTOCH, P. ALBERS, D. BLONDIN (<i>Düsseldorf, Germany</i>)	1087
Association of <i>Cyclin D1</i> Genotypes with Nasopharyngeal Carcinoma Risk. L.-C. SHIH, C.-W. TSAI, M.-H. TSAI, Y.-A. TSOU, W.-S. CHANG, F.-J. LI, M.-H. LEE, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	1093
Twice-daily Dosing of Temozolomide in Combination with Fotemustine for the Treatment of Patients with Refractory Glioblastoma. M. SANTONI, A. PACCAPELO, L. BURATTINI, A. ONOFRI, S. CASCINU (<i>Ancona, Italy</i>)	1099
Interstitial Lung Disease Associated with Docetaxel in Patients with Advanced Non-small Cell Lung Cancer. A. TAMIYA, T. NAITO, S. MIURA, S. MORII, A. TSUYA, Y. NAKAMURA, K. KAIRA, H. MURAKAMI, T. TAKAHASHI, N. YAMAMOTO, M. ENDO (<i>Shizuoka, Japan</i>)	1103
Erlotinib Treatment in Patients with Advanced Lung Adenocarcinoma with CISH-positive and CISH-negative <i>EGFR</i> Gene Alterations. M.-M. HOU, S.-F. HUANG, H.-P. KUO, C.-T. YANG, Y.-H. TSAI, C.-T. YU, H.-C. LIN, C.-H. CHEN, C.-L. WANG, F.-T. CHUNG, J.-J. HSIEH, T. HSU, H.-Y. CHENG, L.-Y. OU, H.-M. WANG, Y.-C. LIN, N.-J. CHANG, J.W.-C. CHANG (<i>Taoyuan; Zhunan; Taipei; Keelung, Taiwan, ROC</i>)	1107
No Consistent Relationship of Glioblastoma Incidence and Cytomegalovirus Seropositivity in Whites, Blacks, and Hispanics. S. LEHRER, S. GREEN, L. RAMANATHAN, K. ROSENZWEIG, V. LABOMBARDI (<i>New York, NY, USA</i>)	1113
Errata	1117

* Reviews (pages 873, 947, 989, 997, 1005)

Integrated Genomic Characterization of the Kallikrein Gene Locus in Cancer. A.H. GIRGIS, A. BUI, N.M. WHITE, G.M. YOUSEF (<i>Toronto, ON, Canada</i>)	957
Small Cell Osteosarcoma Successfully Treated by High-dose Ifosfamide and Methotrexate, Combined with Carboplatin and Pirarubicin. H. FUTANI, S. FUKUNAGA, Y. TSUKAMOTO, N. TERADA, J. ONO, N. OKAMOTO, Y. OTSUKA, T. TANIZAWA, M. TOMATSURI, S. YOSHIYA (<i>Kobe, Hyogo, Japan</i>)	965
Phase I Study of Sunitinib plus Modified FOLFOX6 in Japanese Patients with Treatment-naïve Colorectal Cancer. T. YOSHINO, K. YAMAZAKI, T. HAMAGUCHI, Y. SHIMADA, K. KATO, H. YASUI, N. BOKU, M.J. LECHUGA, T. HIROHASHI, A. SHIBATA, SA. HASHIGAKI, Y. LI, A. OHTSU (<i>Kashiwa, Chiba; Shizuoka; Tokyo, Japan; Milan, Italy</i>)	973
Vitamin D and Pancreatic Cancer Risk – No U-Shaped Curve. L.L. BAGGERLY, C.F. GARLAND (<i>Encinitas; San Diego, CA, USA</i>)	981
Simultaneous Multianalyte Immunoassay Measurement of Five Serum Tumor Markers in the Detection of Colorectal Cancer. FRANCO LUMACHI, FILIPPO MARINO, ROCCO ORLANDO, GIORDANO B. CHIARA, STEFANO M.M. BASSO (<i>Padova; Pordenone, Italy</i>)	985
* Review: Modulation of Systemic and Intestinal Immune Response by Interleukin-2 Therapy in Gastrointestinal Surgical Oncology. Personal Experience in the Context of Current Knowledge and Future Perspectives. L. NESPOLI, F. UGGERI, F. ROMANO, A. NESPOLI, F. BRIVO, L. FUMAGALLI, M. SARGENTI, F. UGGERI, L. GIANOTTI (<i>Monza; Cinisello Balsamo; Lecco; Milan, Italy</i>)	989
* Review: Immunotherapy Approaches Targeting Regulatory T-Cells. H. ONISHI, T. MORISAKI, M. KATANO (<i>Fukuoka, Japan</i>)	997
* Review: Chemoprevention of Asbestos-linked Cancers: A Systematic Review. M. NERI, D. UGOLINI, S. BOCCIA, P.A. CANESSA, A. CESARIO, G. LEONCINI, L. MUTTI, S. BONASSI (<i>Rome; Genova; Sarzana; Vercelli, Italy</i>)	1005
Association of DNA Double-strand Break Gene <i>XRCC6</i> Genotypes and Lung Cancer in Taiwan. T.-C. HSIA, C.-J. LIU, C.-C. CHU, L.-W. HANG, W.-S. CHANG, C.-W. TSAI, C.-I WU, C.-S. LIEN, W.-L. LIAO, C.-Y. HO, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	1015
Soluble Human Leukocyte Antigen-G Expression in Patients with Ductal and Lobular Breast Malignancy. X. PROVATOPOULOU, E. KALOGERA, A. SAGKRIOTIS, F. ZAGOURI, A. NONNI, G.C. ZOGRAFOS, A. GOUNARIS (<i>Athens, Greece</i>).....	1021
Phase II Study of Panobinostat and Bortezomib in Patients with Pancreatic Cancer Progressing on Gemcitabine-based Therapy. H. WANG, Q. CAO, A.Z. DUDEK (<i>Minneapolis, MN, USA</i>)	1027
Sentinel Lymphadenectomy Compared to Extended Lymphadenectomy in Men with Prostate Cancer Undergoing Prostatectomy. A. PONHOLZER, M. LAMCHE, M. KLITSCH, N. KRAISCHITS, M. HIESS, M. SCHENNER, C. BROSSNER, P. SCHRAMEK (<i>Vienna, Austria</i>)	1033
Progesterin Treatment of Atypical Hyperplasia and Well-differentiated Adenocarcinoma of the Endometrium to Preserve Fertility. M. KOSKAS, E. AZRIA, F. WALKER, D. LUTON, P. MADELENAT, C. YAZBECK (<i>Paris, France</i>).....	1037
Combined Oral Topotecan plus Carboplatin in Relapsed or Advanced Cervical Cancer: A GINECO Phase I-II Trial. J.E. KURTZ, G. FREYER, F. JOLY, L. GLADIEFF, M.C. KAMINSKI, M. FABBRO, A. FLOQUET, A.C. HARDY-BESSARD, N. RABAN, I. RAY-COQUARD, E. PUJADE-LAURAINÉ (<i>Strasbourg; Pierre-Bénite; Caen; Toulouse; Vandoeuvre-lès-Nancy; Montpellier; Bordeaux; Saint Briec; Poitiers; Lyon; Paris, France</i>)	1045

The Expression of CD146 Predicts a Poor Overall Survival in Patients with Adenocarcinoma of the Lung. S. OKA, H. URAMOTO, Y. CHIKAISHI, F. TANAKA (<i>Kitakyushu, Japan</i>)	861
SN-38 Overcomes Chemoresistance of Colorectal Cancer Cells Induced by Hypoxia, through HIF1alpha. K. MURONO, N.H. TSUNO, K. KAWAI, K. SASAKI, K. HONGO, M. KANEKO, M. HIYOSHI, N. TADA, T. NIREI, E. SUNAMI, K. TAKAHASHI, J. KITAYAMA (<i>Tokyo, Japan</i>)	865
* Review: The Role of Canonical WNT Signaling Pathway in Oral Carcinogenesis: A Comprehensive Review. J. NOGUTI, C.F.G. DE MOURA, T. AYAKO HOSSAKA, M. FRANCO, C.T. FUJIYAMA OSHIMA, R.A. DEDIVITIS, D.A. RIBEIRO (<i>São Paulo; Santos, SP, Brazil</i>)	873
Decreased Levels of Histone H3K9me1 Indicate Poor Prognosis in Patients with Renal Cell Carcinoma. S. ROGENHOFER, P. KAHL, S. HOLZAPFEL, A. VON RUECKER, S.C. MUELLER, J. ELLINGER (<i>Bonn; Cologne, Germany</i>)	879
Cytotoxicity of Activated Natural Killer Cells and Expression of Adhesion Molecules in Small-cell Lung Cancer. T. TSUCHIDA, H. YAMANE, N. OCHI, T. TABAYASHI, A. HIRAKI, N. NOGAMI, N. TAKIGAWA, K. KIURA, M. TANIMOTO (<i>Okayama, Japan</i>)	887
CSF-1R Up-regulation Is Associated with Response to Pharmacotherapy Targeting Tyrosine Kinase Activity in AML Cell Lines. M. KOGAN, T. FISCHER-SMITH, R. KAMINSKY, G. LEHMICKE, J. RAPPAPORT (<i>Philadelphia, PA, USA</i>)	893
Expression of Cathepsin-D in Primary Breast Cancer and Corresponding Local Recurrence or Metastasis: An Immunohistochemical Study. D. DIAN, T. VREKOUSSIS, N. SHABANI, I. MYLONAS, C. KUHN, C. SCHINDLBECK, I. NAVROZOGLOU, K. FRIESE, A. MAKRIGIANNAKIS, U. JESCHKE (<i>Munich, Germany; Ioannina; Heraklion, Greece</i>)	901
Silencing of CCDC6 Reduces the Expression of 14-3-3σ in Colorectal Carcinoma Cells. A. THANASOPOULOU, A.G. XANTHOPOULOU, A.K. ANAGNOSTOPOULOS, E.G. KONSTANTAKOU, L.H. MARGARITIS, I.S. PAPASSIDERI, D.J. STRAVOPODIS, G.T. TSANGARIS, E. ANASTASIADOU (<i>Athens, Greece</i>)	907
Impact of Temperature on Cell Death in a Cell-culture Model of Hepatocellular Carcinoma. B. LEBER, U. MAYRHAUSER, B. LEOPOLD, S. KOESTENBAUER, K. TSCHELIESSNIGG, V. STADLBAUER, P. STIEGLER (<i>Graz, Austria</i>)	915
Diagnostic Relevance of Overexpressions of PKC-θ and DOG-1 and KIT/PDGFRα Gene Mutations in Extragastrointestinal Stromal Tumors: A Korean Six-Centers Study of 28 Cases. K.-H. KIM, S.D. NELSON, D.-H. KIM, K.U. CHOI, S.J. KIM, K.-W. MIN, K.-S. JANG, S.S. PAIK, Y.-H. OH, S.W. CHAE, J.H. SOHN, H.J. KIM, Y.K. CHO, B.I. KIM, D.I. PARK, C.I. SOHN, S. OH, S.H. CHOI, Y.J. CHOI, H.-Y. WOO, Y.L. PARK, S.J. PARK, S.H. LEE, S. RYU, S.-I. DO, G. KANG, K. KIM, Y.H. CHO, J.-S. PYO (<i>Daejeon; Seoul; Gyeongnam, Busan, South Korea; Santa Monica, CA, USA</i>)	923

Clinical Studies

Cisplatin with Capecitabine: Tolerance and Activity in a Phase I/II Study Preferentially Enrolling Patients with Gastric Cancer. J. WU, TH. RYAN, B. LEVINSON, E. NEWMAN, H.S. HOCHSTER, F. MUGGIA (<i>New York, NY; New Haven, CT USA</i>)	939
* Review: Is Surgical Trauma Prometastatic? F.J. LEJEUNE (<i>Lausanne, Switzerland</i>)	947
Biweekly Docetaxel Is Better Tolerated than Conventional Three-weekly Dosing for Advanced Hormone-refractory Prostate Cancer. P. HERVONEN, H. JOENSUU, T. JOENSUU, G. CLAES, M. RAY, H. ULRIKA, N. PAUL, L. TIINA, H. AKSELI, Z. IGOR, H. MIRJA, N. STEN, L. MARJAANA, L. ILARI, K.-L. PIRKKO-LIISA (<i>Tampere; Helsinki; Lahti; Oulu; Turku, Finland; Karlstad; Stockholm, Sweden; Dublin, Ireland</i>)	953

Receptor Affinity and Preclinical Biodistribution of Radiolabeled Somatostatin Analogs. M. LAZNICEK, A. LAZNICKOVA, H.R. MAECKE (<i>Hradec Kralove, Czech Republic; Freiburg, Germany</i>)	761
<i>In Vitro</i> Blockade of Adhesion of Breast Cancer Cells to Endothelial Cells Using Anti-inflammatory Drugs. E. BISCHOF, D. LUBS, F. FRITZSCHE, A.-S. MEYER, T. BRUCKNER, C. SOHN, M.H.R. EICHBAUM (<i>Heidelberg, Germany</i>)	767
Tissue Microarray Technique in Evaluation of Proliferative Activity in Invasive Ductal Breast Cancer. C. KOBIERZYCKI, B. PULA, A. WOJNAR, M. PODHORSKA-OKOLOW, P. DZIEGIEL (<i>Wroclaw; Poznan, Poland</i>)	773
Antitumor Activity of an Interleukin-2 Monoclonal Antibody in a Murine Osteosarcoma Transplantation Model. K. KOHYAMA, H. SUGIURA, E. KOZAWA, J. WASA, K. YAMADA, A. NISHIOKA, Y. KAMEI, O. TAGUCHI (<i>Nagoya, Japan</i>)	779
Cetuximab Sensitivity Associated with Oxaliplatin Resistance in Colorectal Cancer. L. EKBLAD, A. JOHNSSON (<i>Lund, Sweden</i>)	783
Methylation of <i>TFPI2</i> No Longer Detected in the Serum DNA of Colorectal Cancer Patients after Curative Surgery. K. HIBI, T. GOTO, A. SHIRAHATA, M. SAITO, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>)	787
Detection of Vimentin Methylation in the Serum of Patients with Gastric Cancer. A. SHIRAHATA, K. SAKURABA, Y. KITAMURA, K. YOKOMIZO, T. GOTOU, M. SAITOU, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (<i>Yokohama, Japan</i>)	791
Antiproliferative and Antitumor Effects of Azacitidine Against the Human Myelodysplastic Syndrome Cell Line SKM-1. S. KIMURA, K. KURAMOTO, J. HOMAN, H. NARUOKA, T. EGO, M. NOGAWA, S. SUGAHARA, H. NAITO (<i>Kyoto, Japan</i>)	795
Transforming Growth Factor Beta Receptor I Inhibitor Sensitizes Drug-resistant Pancreatic Cancer Cells to Gemcitabine. Y.J. KIM, J.S. HWANG, Y.B. HONG, I. BAE, Y.-S. SEONG (<i>Cheonan; Daegu, South Korea; Washington, DC, USA</i>)	799
Fucoanthin Induces <i>GADD45A</i> Expression and G ₁ Arrest with SAPK/JNK Activation in LNCap Human Prostate Cancer Cells. Y. SATOMI (<i>Suzuka, Mie, Japan</i>)	807
Different Radioactivity Uptake between Somatostatin Analogues Labelled with ¹¹¹ In and ^{90/88} Y in Rat Kidney. M. LAZNICEK, A. LAZNICKOVA (<i>Hradec Kralove, Czech Republic</i>)	815
Enhanced Renal Clearance of Vancomycin in Rats with Carcinogen-Induced Osteosarcoma. I. SHIMADA, C. IWATA, S. TAGA, H. TERAMACHI, M. NOMURA, K.-I. MIYAMOTO, H. TSUCIYA, T. WADA, K. KIMURA, R. MATSUSHITA (<i>Kanazawa; Gifu, Japan</i>)	823
Farnesyltransferase Inhibitors: Molecular Evidence of Therapeutic Efficacy in Acute Lymphoblastic Leukemia Through Cyclin D1 Inhibition. C.B. COSTA, J. CASALTA-LOPES, C. ANDRADE, D. MOREIRA, A. OLIVEIRA, A.C. GONÇALVES, V. ALVES, T. SILVA, M. DOURADO, J.M. NASCIMENTO-COSTA, A.B. SARMENTO-RIBEIRO (<i>Coimbra; Lisbon, Portugal</i>)	831
Interleukin-21 Increases Direct Cytotoxicity and IFN- γ Production of <i>Ex Vivo</i> Expanded NK Cells towards Breast Cancer Cells. Y.-K. PARK, D.-J. SHIN, D. CHO, S.-K. KIM, J.-J. LEE, M.-G. SHIN, D.-W. RYANG, J.-S. LEE, M.-H. PARK, J.H. YOON, Y.J. JEGAL (<i>Gwangju; Jeollanamdo; Yesan, South Korea</i>)	839
Proteomic Analysis of Exosome-like Vesicles Derived from Breast Cancer Cells. G. PALAZZOLO, N.N. ALBANESE, G. DI CARA, D. GYGAX, M.L. VITTORELLI, I. PUCCI-MINAFRA (<i>Zurich; Muttenz, Switzerland; Palermo, Italy</i>)	847